Vnitr Lek 2007, 53(6):629-631

Délka antikoagulační léčby a riziko recidiv u TEN - editorial

J. Malý
II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Received: December 4, 2006; Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malý J. Délka antikoagulační léčby a riziko recidiv u TEN - editorial. Vnitr Lek. 2007;53(6):629-631.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hull RD, Raskob GE, Brant RF et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000; 160: 229-236. Go to original source... Go to PubMed...
    2. Hyers TM, Agnelli G, Hull RD et al. Antitrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S-193S. Go to original source... Go to PubMed...
    3. Ridker PM, Goldhaber SZ, Danielson E et al. for the PREVENT Investigators: Long-term, low-intenzity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-1434. Go to original source... Go to PubMed...
    4. Schafer AI Warfarin for venous thromboembolism - walking the dosing tightrope. Editorial. N Engl J Med 2003; 348: 1478-1480.
    5. Kearon C Treatment of Venous Thromboembolism. Circulation 2004; 110: 10-18. Go to original source... Go to PubMed...
    6. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138. Go to original source... Go to PubMed...
    7. Lee AY, Levine MN, Baker RI et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153. Go to original source... Go to PubMed...
    8. Schulman S Low-intensity warfarin therapy prevented recurrent venous thromboembolism. ACP J Club 2003; 139: 42. Go to PubMed...
    9. Palareti G, Legnani C, Cosmi B et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12. Go to original source... Go to PubMed...
    10. Söhne M, Ten Wolde JD, Douketris HR et al. D-dimer as a prognostic marker in patients with pulmonary embolism. Supplement to the Journal of Thrombosis and Haemostasis 2003; P1452.
    11. Palareti G, Legnani C, Cosmi B et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-318. Go to original source... Go to PubMed...
    12. Karetová D Antikoagulační léčba flebotrombóz v ambulantní praxi. Vnitř Lék 2005; 51: 790-794.
    13. Elkelboom JW, Quinian DJ, Douketis JD Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a metaanalysis of the randomised trials. Lancet 2001; 358: 9-15. Go to original source... Go to PubMed...
    14. Kearon C Duration of venous thromboembolism prophylaxis after surgery. Chest 2003; 124 (suppl): 386S-392S.
    15. Geerts WH, Pineo GF, John A et al. Prevention of Venous Thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S. Go to original source... Go to PubMed...
    16. Widimský J, Malý J et al. Akutní plicní embolie a žilní trombóza. Praha: Triton 2005, 381 s.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.